-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9

Benzinga·10/31/2026 00:45:01
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.